Melda Türken, Şükran Köse, Cengiz Ceylan, Ayşe Özkan Acar, Hazal Albayrak, Eren Arkalı

Hepatitis B seroprevalence in hematological oncology patients

Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factorssuch as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. areinvolved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluatedretrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxisin patients with hematological malignancy.Methods: A total of 499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBVDNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) withReal-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated bySPSS for Windows 15.00 statistical program. A value of p

PDF

___

1. Deveci Ö, Tekin A, Günbay SS, Kılıç D, Kaygusuz S, Ağalar C, et al. [Evaluation of HBsAg, anti-HCV, anti-HIV and VDRL test results in blood donors]. J Clin Exp Invest 2011;2:416-9. [Article in Turkish]
2. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 Suppl 1:S1-3.
3. Greeley RD, Semple S, Thompson ND, High P, Rudowski E, Handschur E, et al. Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009. Am J Infect Control 2001;39:663-70.
4. Utkan G, Azap A, Muallaoğlu S, Tokluoğlu S, Durnalı AG, Arslan ÜY, et al. [Hepatitis B and C seroprevalence in cancer patıents: a case control study]. Int J Hematol Oncol 2006;16:103- 7. [Article in Turkish]
5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
6. Turkey Viral Hepatitis Diagnosis and Treatment Guide 2017. Available at: http://www.vhsd.org/tr/page/turkiye-viralhepatitliler-tani-ve-tedavi-kilavuzu-2-7.html May 2017. [Article in Turkish]
7. Uptodate 2017 Hepatitis B virus reactivation associated with immunosuppressive therapy. Available at: www.uptodate.com/contents/hepatitis-b-virus-reactivationassociated-with-immunosuppressive-therapy Dec 18, 2017.
8. Tosun S. [The changing viral hepatitis epidemiology in our country]. Ankem Derg 2013;27(suppl 2):128-34.
9. İnci A, Okay M, Güven D. [HBsAg, Anti-HBs, Anti-HCV and Anti-HIV seroprevalence of the patients applied to Artvin State Hospital]. Viral Hepatit Derg 2013;19:41-4. [Article in Turkish]
10. Şardaş OS, Tekeli E, Koç H, Balık İ, Dağcı Ş, Ertural F. [The prevalence of the hepatitis B virus markers in the haematologıcongologıc patients who had frequently received transfusion]. Turkiye Klinikleri J Med Res 1990;8:171-4. [Article in Turkish]
11. Sarı R, Özkan Hİ, Sevinç A, Aydoğdu İ. [Seropositivity of hepatitis B and hepatitis C viruses in blood and blood products in transfused and non-transfused patients with hematological malignancies]. Turgut Özal Tıp Merkezi Dergisi 2000;7:109-12. [Article in Turkish]
12. Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr 2011;29:652-5.
13. Yalçıntaş Arslan Ü, Önder FO, Uncu D, Tokluoğlu S, Gök Durnalı A, Çelenkoğlu G, et al. [Hepatitis B and C Virüs Seroprevalance of the Patients vvith Non-Hodgkin’s Lymphoma: Single Center Experience]. Acta Oncologica Turcica 2009;42:27- 9. [Article in Turkish]
14. Huang B, Li J, Zhou Z, Zheng D, Liu J, Chen M. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma 2012;53: 270-4.
15. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012;25:142-63.
16. Baghbanian M, Halvani M, Roghani HS, Lofti MH, Yazdi MF, Vahedian-Ardakani HA. Prevalence of occult hepatıtıs B infectıon in Iranian cancer patients before chemotherapy treatment. Arq Gastroenterol 2016;53:175-9.